The Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS)
The THESEUS team includes people with hidradenitis suppurativa, dermatologists, GPs, surgeons and research experts.
Hidradenitis suppurativa is a long term, painful skin condition that affects approximately 1% of adults. It involves boils in areas such as the armpits and groins. The THESEUS study has been developed to inform the design of future hidradenitis suppurativa trials and will help us to understand how hidradenitis suppurativa treatments are currently used. The study has been developed with the support of the UK Dermatology Clinical Trials Network
Interested in taking part? More details on what the study involves, who can take part and where the study is recruiting are listed in the following sections.
What does THESEUS involve?
THESEUS is investigating five treatments: two medicines (doxycycline, clindamycin & rifampicin), two types of surgery (deroofing and excision), and laser treatment. Further details about what each of these treatment choices entails can be found in the treatment decision grid.
The choice of treatment will be decided by the participant and their doctor, and will depend upon what treatment is available locally and severity of disease.
For full details of what's involved in taking part in this study, please see the patient information leaflet.
Who can take part in the study?
You may be eligible to take part in the THESEUS study if you:
- Are 18 years of age or older
- Have a diagnosis of active hidradenitis suppurativa which is not controlled by your current treatment.
You would not be eligible to take part if you are pregnant or breast feeding.
Who do I contact about participating in the study?
The table below details the hospital sites involved in the THESEUS study. If you are close to one of these hospitals and are interested in taking part in the study, please get in touch using the email or telephone contact information below.
Clinic visits will be arranged to fit with normal clinic appointments. Please note that we are not able to reimburse travel costs.
Who is funding the study?
The research is being funded by the UK Government, through the National Institute of Health Research Health Technology Assessment (NIHR HTA) programme.
Population-based Clinical Practice Research Datalink studyusing algorithm modelling to identify the true burden of hidradenitis suppurativa
J.R. Ingram et al. British Journal of Dermatology (2018)
A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process
L. Thorlacius and J.R. Ingram et al. British Journal of Dermatology (2018)
Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality
J.R. Ingram et al. British Journal of Dermatology (2016)
The Hidradenitis Suppurativa Priority Setting Partnership
J.R. Ingram et al. British Journal of Dermatology (2014)
This study is funded by the National Institute for Health Research (NIHR) [Health Technology Assessment Programme (HTA Project: 17/98/01)]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.